The effect of vitamin D supplementation on the progression of benign prostatic hyperplasia: A randomized controlled trial

Published:November 07, 2020DOI:


      Background and aims

      Inflammation and proliferation are the cause of benign prostatic hyperplasia (BPH) and are the key components of its mechanism of action. In this study we sought to determine the role of 25-hydroxyvitamin D in BPH, because of its anti-inflammatory activities, and its effect on prostate volume and BPH symptoms.


      This randomized clinical trial (RCT) was conducted on 108 participants >50 years of age who had either asymptomatic or mild BPH symptoms according to the International Prostate Symptom Score (IPSS) questionnaire. Patients were randomly divided into two groups, intervention and control. The intervention group received 50 000 units of vitamin D3 and the control group received a placebo every two weeks for six months. Prostate ultrasound, routine clinical examinations, toucher rectal (TR), and laboratory tests were performed for all patients. After six months, the patients underwent another ultrasound evaluation, measurement of prostate-specific antigen (PSA) levels and completed the IPSS. Results of the evaluations before and after the intervention were compared between the groups using the chi-square, t-test, and logistic regression analysis. Repeated measure analysis was used to evaluate the effect of vitamin D intervention on the changes in the IPSS score.


      The mean age of the participants was 56 ± 9 years. In the control group, the mean prostate volume was higher compared to the intervention group (p < 0.001). The control group had a higher mean PSA level than the intervention group (p < 0.001). Although the IPSS score decreased over time in both groups, analysis of variance showed that the amount of change or decrease in IPSS score in the intervention group was significantly more than the control group (p < 0.001).


      The results of our study support the effect of vitamin D in reducing prostate volume and PSA levels, and in improving BPH symptoms. Further studies are needed to confirm these findings to verify the use of vitamin D as a treatment for BPH.


      To read this article in full you will need to make a payment
      Subscribe to Clinical Nutrition
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • National Institute of Diabetes D
        • Kidney Diseases
        Prostate enlargement: benign prostatic hyperplasia: national institute of diabetes and digestive and kidney diseases.
        National Institutes of Health, 1998
        • Das K.
        • Buchholz N.
        Benign prostate hyperplasia and nutrition.
        Clinical nutrition ESPEN. 2019; 33: 5-11
        • Galeone C.
        • Pelucchi C.
        • Talamini R.
        • Negri E.
        • Dal Maso L.
        • Montella M.
        • et al.
        Onion and garlic intake and the odds of benign prostatic hyperplasia.
        Urology. 2007; 70: 672-676
        • Espinosa G.
        Nutrition and benign prostatic hyperplasia.
        Curr Opin Urol. 2013; 23: 38-41
        • Suzuki S.
        • Platz E.A.
        • Kawachi I.
        • Willett W.C.
        • Giovannucci E.
        Intakes of energy and macronutrients and the risk of benign prostatic hyperplasia.
        AJCN (Am J Clin Nutr). 2002; 75: 689-697
        • Kyprianou N.
        • Tu H.
        • Jacobs S.C.
        Apoptotic versus proliferative activities in human benign prostatic hyperplasia.
        Hum Pathol. 1996; 27: 668-675
        • Ficarra V.
        • Rossanese M.
        • Zazzara M.
        • Giannarini G.
        • Abbinante M.
        • Bartoletti R.
        • et al.
        The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy.
        Curr Urol Rep. 2014; 15: 463
        • Handisurya A.
        • Steiner G.E.
        • Stix U.
        • Ecker R.C.
        • Pfaffeneder-Mantai S.
        • Langer D.
        • et al.
        Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate.
        Prostate. 2001; 49: 251-262
        • Steiner G.E.
        • Stix U.
        • Handisurya A.
        • Willheim M.
        • Haitel A.
        • Reithmayr F.
        • et al.
        Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue.
        Lab Invest. 2003; 83: 1131-1146
        • Royuela M.
        • De Miguel M.
        • Ruiz A.
        • Fraile B.
        • Arenas M.
        • Romo E.
        • et al.
        Interferon-g and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression.
        Eur Cytokine Netw. 2000; 11: 119-127
        • Peehl D.M.
        • Skowronski R.J.
        • Leung G.K.
        • Wong S.T.
        • Stamey T.A.
        • Feldman D.
        Antiproliferative effects of 1, 25-dihydroxyvitamin D3 on primary cultures of human prostatic cells.
        Canc Res. 1994; 54: 805-810
        • Skowronski R.J.
        • Peehl D.M.
        • Feldman D.
        Vitamin D and prostate cancer: 1, 25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines.
        Endocrinology. 1993; 132: 1952-1960
        • Kahokehr A.
        • Vather R.
        • Nixon A.
        • Hill A.G.
        Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials.
        BJU Int. 2013; 111: 304-311
        • Adorini L.
        • Penna G.
        • Fibbi B.
        • Maggi M.
        Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia.
        Ann N Y Acad Sci. 2010; 1193: 146-152
        • Wu-Wong J.R.
        • Tian J.
        • Goltzman D.
        Vitamin D analogs as therapeutic agents: a clinical study update.
        Curr Opin Invest Drugs. 2004; 5: 320
        • DeLuca H.F.
        Overview of general physiologic features and functions of vitamin D.
        AJCN (Am J Clin Nutr). 2004; 80: 1689S-1696S
        • Espinosa G.
        • Esposito R.
        • Kazzazi A.
        • Djavan B.
        Vitamin D and benign prostatic hyperplasia--a review.
        Can J Urol. 2013; 20: 6820-6825
        • Tiwari A.
        Advances in the development of hormonal modulators for the treatment of benign prostatic hyperplasia.
        Expet Opin Invest Drugs. 2007; 16: 1425-1439
        • Hanchette C.L.
        • Schwartz G.G.
        Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation.
        Cancer. 1992; 70: 2861-2869
        • Xu Y.
        • Shao X.
        • Yao Y.
        • Xu L.
        • Chang L.
        • Jiang Z.
        • et al.
        Positive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: new findings from an updated meta-analysis.
        J Canc Res Clin Oncol. 2014; 140: 1465-1477
        • Wilson K.M.
        • Shui I.M.
        • Mucci L.A.
        • Giovannucci E.
        Calcium and phosphorus intake and prostate cancer risk: a 24-y follow-up study.
        AJCN (Am J Clin Nutr). 2015; 101: 173-183
      1. Schwartz G.G. Vitamin D in health and disease: vitamin D and the epidemiology of prostate cancer. Seminars in dialysis. Wiley Online Library, 2005
        • Murphy A.B.
        • Nyame Y.A.
        • Batai K.
        • Kalu R.
        • Khan A.
        • Gogana P.
        • et al.
        Does prostate volume correlate with vitamin D deficiency among men undergoing prostate biopsy?.
        Prostate Cancer Prostatic Dis. 2017; 20: 55-60
        • Haghsheno M.-A.
        • Mellström D.
        • Behre C.-J.
        • Damber J.-E.
        • Johansson H.
        • Karlsson M.
        • et al.
        Low 25-OH vitamin D is associated with benign prostatic hyperplasia.
        J Urol. 2013; 190: 608-614
        • Zhang W.
        • Zheng X.
        • Wang Y.
        • Xiao H.
        Vitamin D deficiency as a potential marker of benign prostatic hyperplasia.
        Urology. 2016; 97: 212-218
        • Colli E.
        • Rigatti P.
        • Montorsi F.
        • Artibani W.
        • Petta S.
        • Mondaini N.
        • et al.
        BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial.
        Eur Urol. 2006; 49: 82-86
        • Caretta N.
        • Vigili de Kreutzenberg S.
        • Valente U.
        • Guarneri G.
        • Pizzol D.
        • Ferlin A.
        • et al.
        Hypovitaminosis D is associated with lower urinary tract symptoms and benign prostate hyperplasia in type 2 diabetes.
        Andrology. 2015; 3: 1062-1067
        • Zendedel A.
        • Gholami M.
        • Anbari K.
        • Ghanadi K.
        • Bachari E.C.
        • Azargon A.
        Effects of vitamin D intake on FEV1 and COPD exacerbation: a randomized clinical trial study.
        Global J Health Sci. 2015; 7: 243
        • Russell R.M.
        Vitamin and trace mineral deficiency and excess.
        Harrison’s Princ Int Med. 2005; 1 (2735–2735)
        • Wong CK-h
        • Choi E.P.-H.
        • Chan S.W.-H.
        • Tsu JH-l
        • Fan C-w
        • Chu PS-k
        • et al.
        Use of the international prostate symptom score (IPSS) in Chinese male patients with benign prostatic hyperplasia.
        Aging Male. 2017; 20: 241-249
        • Crescioli C.
        • Maggi M.
        • Vannelli G.B.
        • Luconi M.
        • Salerno R.
        • Barni T.
        • et al.
        Effect of a vitamin D3 analogue on keratinocyte growth factor-induced cell proliferation in benign prostate hyperplasia.
        J Clin Endocrinol Metabol. 2000; 85: 2576-2583
        • Morelli A.
        • Vignozzi L.
        • Filippi S.
        • Vannelli G.B.
        • Ambrosini S.
        • Mancina R.
        • et al.
        BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder.
        Prostate. 2007; 67: 234-247
        • Taniguchi K.
        • Katagiri K.
        • Kashiwagi H.
        • Harada S.
        • Sugimoto Y.
        • Shimizu Y.
        • et al.
        A novel nonsecosteroidal VDR agonist (CH5036249) exhibits efficacy in a spontaneous benign prostatic hyperplasia beagle model.
        J Steroid Biochem Mol Biol. 2010; 121: 204-207
        • Safwat A.S.
        • Hasanain A.
        • Shahat A.
        • AbdelRazek M.
        • Orabi H.
        • Hamid S.K.A.
        • et al.
        Cholecalciferol for the prophylaxis against recurrent urinary tract infection among patients with benign prostatic hyperplasia: a randomized, comparative study.
        World J Urol. 2019; 37: 1347-1352
        • Kristal A.R.
        • Arnold K.B.
        • Schenk J.M.
        • Neuhouser M.L.
        • Goodman P.
        • Penson D.F.
        • et al.
        Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
        Am J Epidemiol. 2008; 167: 925-934
        • Penna G.
        • Fibbi B.
        • Amuchastegui S.
        • Corsiero E.
        • Laverny G.
        • Silvestrini E.
        • et al.
        The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kB pathways.
        Prostate. 2009; 69: 480-493
        • Vaughan C.P.
        • Tangpricha V.
        • Motahar-Ford N.
        • Goode P.S.
        • Burgio K.L.
        • Allman R.M.
        • et al.
        Vitamin D and incident urinary incontinence in older adults.
        Eur J Clin Nutr. 2016; 70: 987-989
        • Nunes S.B.R.
        • de Matos Oliveira F.
        • Neves A.F.
        • Araujo G.R.
        • Marangoni K.
        • Goulart L.R.
        • et al.
        Association of vitamin D receptor variants with clinical parameters in prostate cancer.
        SpringerPlus. 2016; 5: 364